The Bull Rankings scorecard — our quality-growth score is 18.1 / 100, built from three pillars scored 0–100: Quality 15, Growth 14, Value 28 (valuation is judged against sector peers).
The thesis
Moderna’s current price of $143.77 sits on a P/S of 25.8, a lofty figure given the company’s steep revenue decline of -39.9 % YoY. Our Bull Rankings model assigns a quality‑growth score of 18.1/100, with Value at 28 and Growth at 14. The model’s strongest pillar is Value, yet even that score sits on the expensive side of peers. The weakest pillar is Growth, reflecting the company’s negative revenue trajectory.
Given that the model flags “Earnings outpace cash” and “Diluting shareholders” as cautionary signals, the evidence argues for caution. The stock’s current valuation embeds far more optimism than current results support, and the negative free‑cash‑flow of -$1.2 b confirms that the business is not yet generating sustainable cash. Therefore, the thesis is: Moderna is overvalued for its present growth prospects; the price looks vulnerable unless a sharp turnaround in revenue and cash generation materializes.
What the business actually is
Moderna sells messenger‑RNA medicines across several therapeutic arenas. Its respiratory vaccines line—Spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza—targets the United States, Europe, and global markets. The company is also developing latent vaccines for cytomegalovirus, Epstein‑Barr virus, and HIV, enteric virus products like norovirus, and public‑health vaccines such as Zika, Nipah, and Mpox. In addition, Moderna develops oncology therapeutics (intismeran autogene, cancer antigen therapy, T‑cell engager, cell‑therapy enhancer) and rare‑disease products. Nearly all revenue today comes from respiratory vaccines; the oncology and rare‑disease programs are still in development.
Why it can (or can't) keep compounding
The durability of Moderna’s moat hinges on its proprietary mRNA platform, which enables rapid vaccine development and manufacturing scalability. However, a negative ROE of -46.6 % shows the business is losing money, even with little leverage (debt‑to‑equity of 0.19). The beta of 1.11 signals that the stock moves in line with market volatility, offering no defensive cushion. The model’s “Earnings outpace cash” signal shows reported results look better than the cash the business actually produces, limiting the ability to reinvest or return value to shareholders. Competitors with established vaccine pipelines and larger cash reserves can replicate mRNA technology faster, eroding any competitive advantage.
The valuation question
At $143.77 and a P/S of 25.8, the stock trades at a steep premium to most healthcare peers on sales. Our reverse DCF has no read here, so the anchor is the -39.9 % revenue decline observed in FY YoY. Paying that multiple for a shrinking business means the market is looking past the decline to future products. If the company were to sustain a modest decline, the P/S would still be excessive; conversely, a further contraction would justify a sharper price drop. Thus, the current price reflects an optimistic bias that is not supported by the underlying financials.
The bear case
The most compelling skeptic’s argument is the negative free‑cash‑flow of -$1.2 b. Cash outflows of this magnitude, coupled with a -39.9 % revenue decline, signal that Moderna is burning through capital without generating returns. The “Diluting shareholders” signal further erodes value, as share‑based compensation and potential equity issuances dilute existing equity holders. If the company cannot reverse its cash burn trend within the next 12–18 months, the share price will likely adjust downward to reflect the true cost of capital and growth prospects.
What would change our mind
- Revenue rebound to a positive figure: A turnaround in vaccine sales would lift the growth pillar from 14 to a more respectable level, improving the quality‑growth score.
- Free‑cash‑flow turning positive: Achieving a positive FCF would eliminate the “Earnings outpace cash” caution and demonstrate operational efficiency.
- A major approval outside respiratory vaccines, such as in oncology, would broaden the revenue base beyond a shrinking franchise.
If any of these thresholds are crossed, the model’s weak Growth pillar would strengthen, and the valuation premium could be justified. Until then, the model’s read remains cautious.